| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及1%整数倍的公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 华邦健康于 2025 年 4 月 22 日面向专业投资者非公开发行可交换公司债券 （以下简称"本期可交换债券"），并于 2025 年 4 月 28 日起在深圳证券交易所挂 牌交易，债券简称"25 华邦 EB"，债券代码"117227"，发行规模 6 亿元，期限 3 年，初始换股价格为 14.88 元/股。2025 年 4 月 30 日，因公司实施 2024 年度权 - 1 - 益分派，"25 华邦 EB" 的换股价格由 14.88 元/股调整为 14.83 元/股。 "25 华邦 EB"于 2025 年 10 月 23 日进入换股期，换股期限为 2025 年 10 月 23 日起至 2028 年 4 ...

Core Viewpoint - The company, Kaisheng New Materials (301069.SZ), has not yet engaged in direct business cooperation with Tesla as of the current date [1] Summary by Relevant Categories - **Company Status** - Kaisheng New Materials has confirmed that it has not established any direct business collaboration with Tesla up to now [1]

Core Viewpoint - Kaisheng New Materials, a leading global producer of thionyl chloride, is positioned for future growth with strong financial performance and technological advancements in its product offerings [2][5]. Group 1: Company Overview - Established on December 20, 2005, Kaisheng New Materials was listed on the Shenzhen Stock Exchange on September 27, 2021, with its headquarters in Zibo, Shandong Province [1]. - The company specializes in fine chemical products and new polymer materials, leveraging its technological and industrial chain advantages [1]. Group 2: Financial Performance - For Q3 2025, Kaisheng New Materials reported revenue of 774 million yuan, ranking 10th in the industry, significantly lower than the top competitor, Satellite Chemical, which had revenue of 34.77 billion yuan [2]. - The company's net profit for the same period was 116 million yuan, ranking 2nd in the industry, only behind Satellite Chemical's 3.76 billion yuan [2]. Group 3: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 29.18%, down from 32.70% year-on-year, and below the industry average of 46.56%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 27.78%, an increase from 23.87% year-on-year, and higher than the industry average of 11.02%, reflecting robust profitability [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.54% to 31,400, while the average number of circulating A-shares held per shareholder increased by 4.55% to 12,500 [5]. - Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 2.6049 million shares, a decrease of 647,300 shares from the previous period [5]. Group 5: Future Outlook - Analysts at Huazheng Securities project that Kaisheng New Materials will achieve net profits of 145 million yuan, 190 million yuan, and 250 million yuan for the years 2025 to 2027, with corresponding price-to-earnings ratios of 69, 53, and 40 times [5]. - The company is expected to benefit from the upcoming ramp-up of PEKK production, filling a domestic technological gap, and has already commenced 1,000 tons/year production capacity [5].

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及1%整数倍的公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致， 并保证披露的公司相关信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 重要提示： 1.本次权益变动主要系山东凯盛新材料股份有限公司（以下简称"公司"或 "本公司"）控股股东华邦生命健康股份有限公司(以下简称"华邦健康")发行 的华邦健康 2025 年面向专业机构投资者非公开发行可交换公司债券（债券简称 "25 华邦 EB"，债券代码"117227"，以下简称"本次可交换债券"）的债券持 有人换股，导致控股股东持股比例被动从 34.72%减少至 33.68%，权益变动触及 1%的整数倍。 2.本次权益变动不触及要约收购 ...

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及5%整数倍的提示性公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致， 并保证披露的公司相关信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 重要提示： 1、本次权益变动主要系山东凯盛新材料股份有限公司（以下简称"公司" 或"本公司"）控股股东华邦生命健康股份有限公司(以下简称"华邦健康")发 行的华邦健康 2025 年面向专业机构投资者非公开发行可交换公司债券（债券简 称"25 华邦 EB"，债券代码"117227"，以下简称"本次可交换债券"）的债券 持有人换股，导致控股股东持股比例被动从 39.75%减少至 34.72%，权益变动比 例已触及 5%的整数倍。 2025 年 1 ...

股票代码：301069 信息披露义务人：华邦生命健康股份有限公司 住所及通讯地址：重庆市渝北区人和星光大道 69 号 股份变动性质：本次权益变动的方式系信息披露义务人华邦健康发行可交换 债持有人换股导致持股比例降低。 简式权益变动报告书签署日期：2025 年 10 月 28 日 山东凯盛新材料股份有限公司 简式权益变动报告书 上市公司名称：山东凯盛新材料股份有限公司 股票上市地点：深圳证券交易所 股票简称：凯盛新材 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司 信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"准则 15 号"） 及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》及准则 15 号的规定，本报告书已全面披露 了信息披露义务人在山东凯盛新材料股份有限公司中拥有权益的股份变动情况。 四、截至本报告书签署之日，除本报告书披 ...

Core Viewpoint - The company has reported an improvement in the yield rate of its PEKK products and is progressing with market expansion as planned [1] Group 1 - The yield rate of PEKK products has been continuously improving this year [1] - Market development is proceeding according to the company's plans [1]

Group 1 - The core point of the article is that Kaisheng New Materials (301069.SZ) has begun supplying high-purity battery-grade thionyl chloride to relevant production enterprises [1] Group 2 - The company has made a significant step in its production capabilities by providing a specialized chemical product for the battery industry [1]

Core Viewpoint - The company has reported an improvement in the yield rate of its PEKK products and is progressing with market expansion as planned [1] Group 1 - The yield rate of PEKK products has been continuously improving this year [1] - Market development is proceeding according to the company's plans [1]

Core Viewpoint - The company, Kaisheng New Materials, has successfully supplied high-purity battery-grade thionyl chloride to relevant production enterprises [1] Group 1 - The company announced on October 28 that it has begun supplying high-purity battery-grade thionyl chloride [1]